BNTC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	19 742.00
Vidutinė apimtis	82 838.00
Rinkos kapitalizacija	17.89M
EPS	$0 ( 2024-02-12 )
Kita pelno data	( $-0.780 ) 2024-05-13
Last Dividend	$0.0450 ( 2018-06-01 )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.0330 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Banks Jerel A.	Buy	466 554	Options (right to buy)
2024-03-06	Boston Megan	Buy	200 004	Options (right to buy)
2023-12-06	Smith Edward F	Buy	35 000	Options (right to buy)
2023-12-06	Francis Peter	Buy	35 000	Options (right to buy)
2023-12-06	Buchi J Kevin	Buy	35 000	Options (right to buy)

INSIDER POWER
100.00
Last 38 transactions
Buy: 2 361 696 \| Sell: 57 465

Tūris Koreliacija

Ilgas: -0.17 (neutral)

Trumpas: -0.39 (neutral)

Signal:(48.426) Neutral

Benitec Biopharma Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RNLX	0.862
TTSH	0.842
BAFN	0.831
OVLY	0.829
VIOT	0.826
GGAL	0.826
ASLE	0.824
CASH	0.823
BOOM	0.82
TELA	0.818

10 Labiausiai neigiamai susiję koreliacijos
MBCN	-0.811

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Benitec Biopharma Inc Koreliacija - Valiuta/Žaliavos

0.15
( neutral )

0.10
( neutral )

0.00
( neutral )

0.36
( neutral )

-0.14
( neutral )

-0.43
( neutral )

Benitec Biopharma Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$75 000.00
Bruto pelnas:	$-306 000 (-408.00 %)
EPS:	$-14.12

FY	2023
Pajamos:	$75 000.00
Bruto pelnas:	$-306 000 (-408.00 %)
EPS:	$-14.12

FY	2022
Pajamos:	$73 000.00
Bruto pelnas:	$64 000.00 (87.67 %)
EPS:	$-38.62

FY	2021
Pajamos:	$59 000.00
Bruto pelnas:	$-64 000.00 (-108.47 %)
EPS:	$-3.23

Financial Reports:

No articles found.

Benitec Biopharma Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Benitec Biopharma Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0450	2018-06-01
Last Dividend	$0.0450	2018-06-01
Next Dividend	$0	N/A
Payout Date	2018-06-08
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0450	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2018	$0.0450	0.01%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-358.57	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-1.024	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-2.05	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.62	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.55	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.55	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0198	-1.500	9.67	-10.00	[0 - 0.6]
interestCoverageTTM	-1 446.13	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-7.01	2.00	-2.34	-4.67	[0 - 30]
freeCashFlowPerShareTTM	-7.01	2.00	-3.51	-7.01	[0 - 20]
debtEquityRatioTTM	0.0273	-1.500	9.89	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-355.61	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-42.71	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00286	0.800	-3.31	-2.65	[0.5 - 2]
Total Score				-1.934

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.813	1.000	-0.183	0	[1 - 100]
returnOnEquityTTM	-2.05	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-7.01	2.00	-2.34	-7.01	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-7.01	2.00	-2.34	-4.67	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00690	1.500	-3.29	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-296.16	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-3.45

Benitec Biopharma Inc

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.